title: Inhibitory effect of OP-41483.alpha-CD, a prostacyclin analog, on peripheral vascular lesion models in rats.
abstract: The effect of a chemically stable prostacyclin analog, OP-41483 alpha-cyclodextrin clathrate (OP-41483.alpha-CD), on vascular lesions, platelet aggregation and blood pressure were examined and compared with those of prostaglandin E1 alpha-cyclodextrin clathrate (PGE1.CD) in in vivo rat models. 1) In the laurate (1 mg/leg, i.a.)-induced arterial thrombotic model, OP-41483.alpha-CD (1 microgram/kg/min, i.v.) prevented the progression of femoral arterial vascular lesions and enhanced the development of collaterals in the femoral artery. PGE1.CD did not inhibit the progression of vascular damages. 2) In the model of vasoconstriction induced by epinephrine (0.05 mg/tail, s.c.) and ergotamine (2 mg/kg, s.c.), OP-41483.alpha-CD and PGE1.CD, at 1 microgram/kg/min, inhibited the progress of of tail gangrene and lessened the decrease in tail cutaneous blood flow. 3) OP-41483.alpha-CD (1 microgram/kg/min) suppressed the ADP (0.1 mg/kg/min, i.v.)-induced decrease in the number of circulating platelets without affecting the change in blood pressure. In contrast, PGE1.CD (3 micrograms/kg/min) inhibited ADP-induced thrombocytopenia with a decrease in blood pressure. These results indicate that OP-41483.alpha-CD has antiplatelet and cutaneous blood flow improving activities that are greater than its hypotensive effect and may be of therapeutic potential in peripheral vascular diseases.
authors.affiliation: Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Wakitani
authors.forename: T
authors.initials: T
authors.lastname: Takakuwa
authors.forename: M
authors.initials: M
authors.lastname: Sugioka
authors.forename: B
authors.initials: B
authors.lastname: Fujitani
authors.forename: H
authors.initials: H
authors.lastname: Aishita
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D003505:Cyclodextrins / Q000494:pharmacology*; D004837:Epinephrine / Q000494:pharmacology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004878:Ergotamine / Q000494:pharmacology; D005263:Femoral Artery; D007511:Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D007848:Laurates / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013927:Thrombosis / Q000188:drug therapy* / Q000503:physiopathology; D014661:Vasoconstriction; D047391:alpha-Cyclodextrins
chemical_list: D003505:Cyclodextrins; D007848:Laurates; D010975:Platelet Aggregation Inhibitors; D047391:alpha-Cyclodextrins; C043214:prostaglandin E1-alpha-cyclodextrin; C051518:OP 41483-alpha-cyclodextrin; D011464:Epoprostenol; D000527:Alprostadil; D004878:Ergotamine; D004837:Epinephrine